Fresenius Medical Care AG & Co.’s (FMS) “Neutral” Rating Reiterated at Royal Bank of Canada
Royal Bank of Canada reissued their neutral rating on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) in a report published on Monday, Borsen Zeitung reports.
FMS has been the subject of several other research reports. Barclays upgraded shares of Fresenius Medical Care AG & Co. from an equal weight rating to an overweight rating and set a $40.23 price target for the company in a research report on Thursday, June 20th. DZ Bank reaffirmed a neutral rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday, July 30th. BTIG Research downgraded shares of Fresenius Medical Care AG & Co. from a buy rating to a neutral rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Fresenius Medical Care AG & Co. from a hold rating to a sell rating and set a $41.00 price objective on the stock. in a report on Monday, July 1st. Finally, Commerzbank reaffirmed a hold rating and set a $54.00 price objective on shares of Fresenius Medical Care AG & Co. in a report on Thursday, May 9th. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. Fresenius Medical Care AG & Co. currently has a consensus rating of Hold and an average target price of $53.05.
FMS opened at $33.41 on Monday. The firm has a market cap of $20.33 billion, a P/E ratio of 14.72, a PEG ratio of 2.43 and a beta of 1.44. The firm has a 50-day moving average of $36.37 and a 200 day moving average of $38.51. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.76 and a current ratio of 0.99. Fresenius Medical Care AG & Co. has a fifty-two week low of $30.99 and a fifty-two week high of $53.40.
About Fresenius Medical Care AG & Co.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading: Options Trading – Understanding Strike Price
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.